Abstract: Background: Patients may experience discomfort from ureteric stents, which is mostly related to smooth muscle spasm, urine reflux into the ureters, and irritation of the bladder mucosa. The present study was conducted to compare Mirabegron and Tamsulosin in treating Stent related Lower Urinary Tract Symptoms after Urological Procedure.

Material and Methods: This prospective, randomized, double-blind, placebo-controlled trial included 150 patients undergoing urological procedures with DJ stent placement. Participants were randomly allocated into three groups: Group I (Tamsulosin 0.4 mg), Group II (Mirabegron 50 mg), and Group III (Placebo). Symptom assessments were conducted using International Prostate Symptom Score (IPSS) and Urological Stent-Related Symptom Score (USSRS) at postoperative Day 1, after 3 weeks of intervention, and 3 weeks after stent removal. Data analysis included ANOVA and chi-square tests, with a p-value <0.05 considered significant.

Results: The Mirabegron group demonstrated significantly lower USSRS urinary symptom scores (26.3 ± 3.8) and body pain scores (17.6 ± 3.2) compared to Tamsulosin (32.5 ± 4.1, 27.2 ± 3.6) and Placebo (35.1 ± 4.5, 30.5 ± 3.9) (p=0.02, p=0.01). Additionally, IPSS storage and irritative subscores were significantly lower in the Mirabegron group (p=0.01, p=0.02), with superior improvements in Quality of Life (QoL) scores (p=0.05). Symptom relief was consistent at Day 1, after 3 weeks of intervention, and after 3 weeks post-stent removal.

Conclusion: Mirabegron 50 mg proved significantly more effective than Tamsulosin 0.4 mg and placebo in managing ureteral stent-related symptoms, showing superior outcomes in reducing urinary symptoms, body pain, and improving QoL. These findings position Mirabegron as a preferred monotherapy for managing ureteral stent-related discomfort.